Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate in children with congenital adrenal hyperplasia
NCT03548246Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I) in congenital adrenal hyperplasia (CAH), sponsored by UT Southwestern Medical Center. Planned start Jan 2023; status: withdrawn.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03548246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548246.